Dr. Mark Ranalli
Claim this profileNationwide Children's Hospital
Expert in Uterine Tumors
Expert in Neuroblastoma
71 reported clinical trials
125 drugs studied
About Mark Ranalli
Education:
- Obtained MD from The Ohio State University College of Medicine in 2006.
- Completed Residency in Pediatrics at Nationwide Children's Hospital (2006-2009).
- Undertook Fellowship in Pediatric Cardiology at Nationwide Children's Hospital (2009-2012).
Experience:
- Currently serving as a Pediatric Cardiologist at Nationwide Children's Hospital.
Area of expertise
1Uterine Tumors
Global LeaderStage I
Stage IV
Stage II
2Neuroblastoma
Global LeaderMYC positive
Stage IV
MYC negative
Affiliated Hospitals
Clinical Trials Mark Ranalli is currently running
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
DAY101
for Langerhans Cell Histiocytosis
This trial tests the safety and effectiveness of tovorafenib (DAY101) in children and young adults with Langerhans cell histiocytosis that is worsening, has returned, or does not respond to other treatments. Tovorafenib is taken orally and works by blocking enzymes needed for cancer cell growth. The study aims to find the best dose and observe the response and side effects over time.
Recruiting1 award Phase 228 criteria
More about Mark Ranalli
Clinical Trial Related7 years of experience running clinical trials · Led 71 trials as a Principal Investigator · 24 Active Clinical TrialsTreatments Mark Ranalli has experience with
- Cyclophosphamide
- Radiation Therapy
- Etoposide
- Nivolumab
- Temozolomide
- Vincristine Sulfate
Breakdown of trials Mark Ranalli has run
Uterine Tumors
Neuroblastoma
Lymphoma
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mark Ranalli specialize in?
Mark Ranalli focuses on Uterine Tumors and Neuroblastoma. In particular, much of their work with Uterine Tumors has involved Stage I patients, or patients who are Stage IV.
Is Mark Ranalli currently recruiting for clinical trials?
Yes, Mark Ranalli is currently recruiting for 20 clinical trials in Columbus Ohio. If you're interested in participating, you should apply.
Are there any treatments that Mark Ranalli has studied deeply?
Yes, Mark Ranalli has studied treatments such as Cyclophosphamide, Radiation Therapy, Etoposide.
What is the best way to schedule an appointment with Mark Ranalli?
Apply for one of the trials that Mark Ranalli is conducting.
What is the office address of Mark Ranalli?
The office of Mark Ranalli is located at: Nationwide Children's Hospital, Columbus, Ohio 43205 United States. This is the address for their practice at the Nationwide Children's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.